The Use of AMH to Assess Ovarian Toxicity in Adolescents and Young Adults After Cancer Treatment

Effects of Gonadotropin-Releasing Hormone Analogs on Ovarian Function Against Chemotherapy-Induced Gonadotoxic Effects in Premenopausal Women With Breast Cancer in China

“…Compared with traditional ovarian function indicators, such as follicle-stimulating hormone, luteinizing hormone, and inhibin B, AMH can reflect ovarian reserve relatively sensitively and stably in young women . Although not perfect, AMH is the best available serum marker for assessing ovarian toxic effects in patients after cancer treatment . Our previous research also indicated that AMH is an efficient marker for predicting postchemotherapy ovarian function exclusively in premenopausal female patients with breast cancer older than 35 years .…”

“…14,15 Although not perfect, AMH is the best available serum marker for assessing ovarian toxic effects in patients after cancer treatment. 16 Our previous research also indicated that AMH is an efficient marker for predicting postchemotherapy ovarian function exclusively in premenopausal female patients with breast cancer older than 35 years. 10 In addition, animal experiments showed that high doses of cyclophosphamide (CTX) substantially reduced the number of primordial follicles and decreased serum AMH levels in mice.…”

Fertility Preservation in Adolescents and Young Adults With Cancer: A Case-Based Review

“…The use of anti-M üllerian hormone (AMH) to predict premature ovarian insufficiency in this population is controversial. 51 Although both AMH and antral follicle count are sensitive and reliable markers of ovarian reserve, they have not been shown to predict reproductive potential in women with unproven fertility. However, AMH is a reliable predictor of response to stimulation for oocyte retrieval.…”